ArticleAsian journal of andrology
Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Article in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.The Canadian journal of urology · 2026Trial
- Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study.Investigative and clinical urology · 2023Trial
- Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.Scientific reports · 2025Article
- Associating serum testosterone levels with African ancestral prostate cancer health disparities.Scientific reports · 2025Article
- Testosterone levels at diagnosis: A key predictor of overall survival among patients with prostate cancer.BJUI compass · 2025Article
- Beyond castration: defining maximal testosterone control in advanced prostate cancer.Frontiers in endocrinology · 2025Article
- Effect of deep testosterone reduction on the prognosis of metastatic prostate cancer with high-volume disease.Journal of cancer research and clinical oncology · 2024Article
- Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer.Frontiers in oncology · 2024Article
- Review
- Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.Asian journal of urology · 2020Article
- Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review.Cancer cell international · 2020Review
- Discordance between testosterone measurement methods in castrated prostate cancer patients.Endocrine connections · 2019Article
- Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018Article
- Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Review
- Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy.Asian journal of andrologyArticle
- Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) is the standard of care for patients with metastatic prostate cancer. However, whether serum testosterone levels, using a cut-off point of 50 ng dl-1 , are related to the effective time of ADT in newly diagnosed prostate cancer patients remains controversial. Moreover, recent studies have shown that some patients may benefit from the addition of upfront docetaxel chemotherapy. To date, no studies have been able to distinguish patients who will benefit from the combination of ADT and docetaxel chemotherapy. This study included 206 patients who were diagnosed with metastatic prostate cancer and showed progression to castrate-resistance prostate cancer (CRPC). Serum testosterone levels were measured prospectively after ADT for 1, 3, and 6 months. The endpoint was the time to CRPC. In univariate and multivariate analyses, testosterone levels <50 ng dl-1 were not associated with the effective time of ADT. Receiver operating characteristic and univariate analysis showed that testosterone levels of ≤25 ng dl-1 after the first month of ADT offered the best overall sensitivity and specificity for prediction of a longer time to CRPC (adjusted hazard ratio [HR], 1.46; 95% confidence interval [95% CI], 1.08-1.96; P = 0.013). Our results show that serum testosterone level of 25 ng dl-1 plays a prognostic role in prostate cancer patients receiving ADT. A testosterone value of 25 ng dl-1 after the first month of ADT can distinguish patients who benefit from ADT effectiveness for only a short time. These patients may need to receive ADT and concurrent docetaxel chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.